Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
|Poll|July 18, 2022
POLL: Women are More Likely to Develop Hidradenitis Suppurativa - True or False?
Author(s)Dermatology Times Staff
Click here to answer this week's poll.
Advertisement
True or False: Women are more likely to develop HS than men.
Advertisement
Related to this article
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Improving Early Identification and Escalation of HS
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5